APPG Inquiry into Pancreatic Cancer Research
The APPG announced at it’s AGM in March that it would be holding an Inquiry into pancreatic cancer research. The aim of the Inquiry is to increase funding into research and improve the quality of research taking place. In order for the Inquiry to make a decision about this, they will be accepting both written and verbal evidence from a number of expert witnesses including Ali Stunt, CEO of Pancreatic Cancer Action and pancreatic cancer survivor.
There are four meetings taking place over five months; Monday 12th May, Monday 9th June, Monday 7th July and Monday 8th September.
We welcome the Inquiry and hope that it will be increase the amount of research into pancreatic cancer, and ultimately lead to earlier detection of the disease and better treatment for patients.
You can read the transcript from the first meeting on Monday 12th May here including evidence from Ali Stunt.
At the meetings, Pancreatic Cancer Action is calling for:
- An inquiry into how cancer research funds are distributed between cancer types and why pancreatic cancer receives such a low proportion
- Develop a Pancreatic Cancer Research Strategy in the UK to involve all stakeholders
- Increased levels of government funding to plug the gap for pancreatic cancer
- Invest a greater proportion of research funding into early diagnosis – in particular in the search for a diagnostic biomarker
- Ensure that global collaboration is formalised to prevent duplication of effort (and wasted funds)
- Encourage large cancer research funders such as Cancer Research UK to commit a firm monetary value on their proposed commitment to increase funding where there is identified unmet need (such as pancreatic cancer)
- Encourage greater pharmaceutical/industry research investment in pancreatic cancer
- Change some nihilistic attitudes among funders that pancreatic cancer is not a lost cause
Read the PCA evidence to APPG Inquiry PC Research full report to find out more.
The report looks at the issues relating to the fact that pancreatic cancer has been chronically underfunded for decades, the link to funding and low survival rate and a comparison with other cancers which have received higher levels of funding. In some cases, research funding for some cancers has seen a significant uplift in survival rates.
It also discusses comparisons of pancreatic cancer funding across the world. While proportions of pancreatic cancer research funds in the USA, Canada, Australia and parts of Europe are similar to those in the UK relative to total cancer research funding although the amount of funds in terms of dollars spent are significantly greater.
We will keep you updated with the outcome of each meeting.
APPG Inquiry into Pancreatic Cancer Research Report
For five months in 2014, the All-Party Parliamentary Group on Pancreatic Cancer led an Inquiry into research into pancreatic cancer. The aim was to understand how to increase the amount and quality of research into pancreatic cancer,
On Wednesday 29th October 2014, the Inquiry Report was launched, in an event attended by Secretary of State for Health, Jeremy Hunt MP, Public Health Minister, Jane Ellison, 26 MPs and Peers and other stakeholders from the pancreatic cancer community including patients and others directly affected by pancreatic cancer.
The report lays out a series of key recommendations on ways to improve research and diagnosis, clinical trials, and further investigation into the discrepancy in survival rates across the country.
Some of the most promising recommendations are a commitment to reach a minimum of £10 million site-specific spend from 2015 and an increase in funding to £25 million by 2025, and more research into early diagnosis including a focus on developing on early screening test.
You can read the full report and recommendations here: appg-research-report-2014-final-web-version